ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 897 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Follow-Up Questions
Who is the CEO of ANI Pharmaceuticals Inc?
Mr. Nikhil Lalwani is the President of ANI Pharmaceuticals Inc, joining the firm since 2020.
What is the price performance of ANIP stock?
The current price of ANIP is $96.44, it has decreased 1.06% in the last trading day.
What are the primary business themes or industries for ANI Pharmaceuticals Inc?
ANI Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is ANI Pharmaceuticals Inc market cap?
ANI Pharmaceuticals Inc's current market cap is $2.0B
Is ANI Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for ANI Pharmaceuticals Inc, including 5 strong buy, 7 buy, 2 hold, 0 sell, and 5 strong sell
